Inovio Pharmaceuticals Stock Retained Earnings
| INO Stock | USD 1.92 0.02 1.03% |
Inovio Pharmaceuticals fundamentals help investors to digest information that contributes to Inovio Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Inovio Stock. The fundamental analysis module provides a way to measure Inovio Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Inovio Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Retained Earnings | -1.7 T | -1.6 T | |
| Retained Earnings Total Equity | -1.3 B | -1.3 B |
Inovio | Retained Earnings |
Inovio Pharmaceuticals Company Retained Earnings Analysis
Inovio Pharmaceuticals' Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current Inovio Pharmaceuticals Retained Earnings | (1.73 T) |
Most of Inovio Pharmaceuticals' fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inovio Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Inovio Retained Earnings Driver Correlations
Understanding the fundamental principles of building solid financial models for Inovio Pharmaceuticals is extremely important. It helps to project a fair market value of Inovio Stock properly, considering its historical fundamentals such as Retained Earnings. Since Inovio Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Inovio Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Inovio Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
| Competition |
Based on the latest financial disclosure, Inovio Pharmaceuticals has a Retained Earnings of (1.73 Trillion). This is 185873.51% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The retained earnings for all United States stocks is significantly higher than that of the company.
Inovio Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inovio Pharmaceuticals' direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inovio Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Inovio Pharmaceuticals by comparing valuation metrics of similar companies.Inovio Pharmaceuticals is currently under evaluation in retained earnings category among its peers.
Inovio Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Inovio Pharmaceuticals from analyzing Inovio Pharmaceuticals' financial statements. These drivers represent accounts that assess Inovio Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Inovio Pharmaceuticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 1.4B | 1.0B | 372.3M | 49.7M | 44.7M | 42.5M | |
| Enterprise Value | 1.2B | 1.0B | 358.0M | (53.9B) | (62.0B) | (58.9B) |
Inovio Fundamentals
| Return On Equity | -1.15 | ||||
| Return On Asset | -0.49 | ||||
| Operating Margin | (174.11) % | ||||
| Current Valuation | (11.11 M) | ||||
| Shares Outstanding | 36.67 M | ||||
| Shares Owned By Insiders | 0.68 % | ||||
| Shares Owned By Institutions | 36.60 % | ||||
| Number Of Shares Shorted | 5.38 M | ||||
| Price To Earning | (5.43) X | ||||
| Price To Book | 1.04 X | ||||
| Price To Sales | 326.67 X | ||||
| Revenue | 217.76 K | ||||
| Gross Profit | (75.4 M) | ||||
| EBITDA | (112.4 B) | ||||
| Net Income | (107.25 B) | ||||
| Cash And Equivalents | 348.13 M | ||||
| Cash Per Share | 1.40 X | ||||
| Total Debt | 11.87 B | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 3.17 X | ||||
| Book Value Per Share | 1.90 X | ||||
| Cash Flow From Operations | (104.08 B) | ||||
| Short Ratio | 7.86 X | ||||
| Earnings Per Share | (3.95) X | ||||
| Target Price | 7.83 | ||||
| Beta | 0.92 | ||||
| Market Capitalization | 71.13 M | ||||
| Total Asset | 113.2 B | ||||
| Retained Earnings | (1.73 T) | ||||
| Working Capital | 62.5 M | ||||
| Current Asset | 171.85 M | ||||
| Current Liabilities | 31.47 M | ||||
| Net Asset | 113.2 B |
About Inovio Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Inovio Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inovio Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inovio Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
When determining whether Inovio Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Inovio Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Inovio Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Inovio Pharmaceuticals Stock: Check out Inovio Pharmaceuticals Piotroski F Score and Inovio Pharmaceuticals Altman Z Score analysis. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.95) | Revenue Per Share | Quarterly Revenue Growth 0.14 | Return On Assets | Return On Equity |
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.